the staff of the Ridgewood blog
Ridgewood NJ, Novo Nordisk’s latest obesity treatment medication, amycretin, has shown promising results, with patients shedding 13% of their body weight in a mere 12 weeks. This new drug, which targets GLP-1 and amylin hormones associated with hunger and satiety, may outperform semaglutide in effectiveness. However, before amycretin becomes widely accessible, it must undergo extensive and lengthier trials. The positive outcomes from the initial trials have propelled Novo Nordisk’s stock to surge by up to 8.3%.
Continue reading Novo Nordisk’s Latest Obesity Treatment Shows Promising Results
